Elicio Therapeutics reported second quarter 2026 financial results, posting a net loss of $8.2 million ($0.43 per share) compared to $10.6 million in the prior year period. Research and development expenses decreased to $6.8 million from $7.0 million due to lower clinical trial costs as patients moved into follow-up phases for the Phase 2 AMPLIFY-7P trial, which did not meet its primary endpoint but continues subgroup evaluation. General and administrative expenses rose to $3.6 million from $3.1 million driven by increased headcount. The company holds $23.5 million in cash and cash equivalents as of June 30, 2026, with a July 2026 registered direct financing providing approximately $15.0 million in gross proceeds to support operations into the first quarter of 2027. Elicio plans to initiate a Phase 1 combination study for its lead candidate ELI-002 7P in metastatic pancreatic cancer in Q4 2026 and activated an investigator-initiated Phase 1 neoadjuvant trial led by Memorial Sloan Kettering Cancer Center. The company operates as a clinical-stage biotechnology firm developing next-generation immunotherapies for KRAS-driven cancers.

Elicio Therapeutics, Inc. entered into a Securities Purchase Agreement on July 1, 2026, to issue and sell 4,380,313 shares of common stock at $3.43 per share in a registered direct offering to institutional investors. The offering is expected to close on July 6, 2026, and is expected to generate approximately $15 million in gross proceeds. Elicio Therapeutics, Inc. is a biotechnology company focused on developing immunotherapy treatments.

Elicio Therapeutics, Inc. announced preliminary clinical observations supporting the evaluation of ELI-002 7P with checkpoint inhibition and plans to conduct a Phase 1 study in first-line metastatic mutant KRAS pancreatic ductal adenocarcinoma, pending funding. Elicio Therapeutics, Inc. is a biotechnology company focused on developing immunotherapy treatments.

Elicio Therapeutics, Inc. announced the results from its randomized Phase 2 AMPLIFY-7P study in adjuvant mutant KRAS-driven pancreatic ductal adenocarcinoma, while also outlining a refined Phase 3 development strategy for ELI-002 7P. The company is a clinical-stage biotechnology company focused on developing immunotherapy-based cancer vaccines.